Week of August 23rd 2021 | Vol. 10, Issue 34 |
|
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
|
|
For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
|
|
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
|
|
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products
Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US
Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
|
|
Pfizer has strengthened its oncology pipeline with a deal to acquire the clinical stage immuno-oncology company Trillium Therapeutics for $2.26 billion.
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells. Its two lead molecules, TTI-622 and TTI-621, block the signal-regulatory protein α (SIRPα)–CD47 axis, which is emerging as a key immune checkpoint in hematological malignancies. TTI-622 and TTI-621 are novel, potentially best-in-class SIRPα-Fc fusion proteins that are currently in Phase 1b/2 development across several indications, with a focus on hematological malignancies.
“Today’s announcement reinforces our commitment to pursue scientific breakthroughs with the addition of potentially best-in-class molecules to our innovative pipeline,” said Andy Schmeltz, global president and general manager, Pfizer Oncology. “The proposed acquisition of Trillium builds on our strong track record of leadership in oncology, enhancing our hematology portfolio as we strive to improve outcomes for people living with blood cancers around the globe. Our deep experience in understanding the science of blood cancers, along with the diverse knowledge base we have developed across our growing hematology portfolio of eight approved and investigational therapies, provide us with a foundation to advance these important potential medicines to patients who need them.”
|
|
RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
Pharma & Biotech
7 transactions totaling $208 million
Supplies, Equipment & Services
5 transactions totaling $9 million
Healthcare IT & Managed Care
6 transactions totaling $7,434 million
Healthcare Facilities & Distributors
4 transactions totaling $444 million
|
|
Pharma & Biotech
12 transactions totaling $831 million
Supplies, Equipment & Services
7 transactions totaling $28 million
Healthcare IT & Managed Care
7 transactions totaling $58 million
Healthcare Facilities & Distributors
1 transaction totaling $11 million
|
|
Pharma & Biotech
7 transactions totaling $465 million
Supplies, Equipment & Services
3 transactions totaling $43 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
1 transaction totaling $25 million
|
|
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
|
|
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
|
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
|
August 23, 2021 - Fierce Pharma
Health data software provider Inovalon is set to be acquired by Nordic Capital, Insight Partners and other investors in a deal valuing the company at roughly $7.3 billion.
Announced Aug. 18, the deal will take the tech company private and pay out $41 per share in cash to its stockholders—a roughly 25% bump over its value in late July, according to the announcement. Reuters and other sources peg the all-cash deal at $6.41 billion.
August 23, 2021 - Fierce Biotech
Back in March, the pair signed a deal worth $600 million in an upfront/biobucks mix to tap Genevant’s lipid nanoparticle (LNP) tech to work on nucleic acid therapeutics to target treat liver fibrosis.
Now, the Japanese pharma, which has dozens of deals with European and U.S. biotechs, is back at the table, penning a $303 million upfront/biobucks pact to again pen its LNP nonviral gene therapy tech and, also again, to target liver disease, but this time for two undisclosed rare liver diseases.
August 20, 2021 - Fierce Pharma
Riding a global craze for mRNA tech, China's Abogen Biosciences has raised a whopping $700 million in a series C. Eli Lilly and Innovent Biologics' PD-1 inhibitor Tyvyt posted a phase 3 win in previously untreated stomach cancer. China's artificial intelligence drug miner XtalPi has reeled in a $400 million series D. And more.
August 20, 2021 - Fierce Pharma
Regeneron's Roche-partnered monoclonal antibody, dubbed REGEN-COV in the U.S., has scored a nod from the U.K.'s drug regulator to treat and prevent COVID-19.
AstraZeneca has finally caught a break with promising late-stage trial data for its long-acting antibody cocktail.
|
|
Events Hosted or Attended by Bourne Partners
October 20, 2021 - Charlotte, NC
November 9-11, 2021 - Milan, Italy
January 10-14, 2022 - San Francisco, CA
|
|
Welcome to Bourne, let's talk.
Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.
|
|
|
|
|
|
|
